Tirzepatide participants were more likely than placebo participants to meet a combined weight, blood pressure and cholesterol target in an exploratory analysis of four SURMOUNT trials. The analysis counted how often the same person reached all three thresholds [1].
How the targets were measured
The weight-loss tool focuses on changes in body weight. This analysis also required a change in systolic blood pressure and a specific non-HDL cholesterol level. Researchers evaluated each trial separately at week 72 in SURMOUNT-1 through -3 and week 88 in SURMOUNT-4 [1].
Eli Lilly funded the analysis. It used on-treatment data from participants with baseline and at least one follow-up measurement for each measure. The authors estimated missing endpoint measurements from available data. Treatment comparisons had P < .001 without adjustment for multiple comparisons[1].
How many participants reached all three
With a weight-loss threshold of at least 5%, the paper’s reported ranges were 32–38% with tirzepatide and 2–8% with placebo. At the 10% threshold the ranges were 28–37% and 1–5%, and at the 15% threshold they were 22–34% and 1–3%. The placebo ranges refer to groups that started on placebo [1].
SURMOUNT-4 used a withdrawal design. Everyone received tirzepatide for 36 weeks before randomization to continue it or switch to placebo. Of those who switched, 14%, 10% and 8% met all three criteria using the 5%, 10% and 15% weight-loss thresholds, respectively [1].
What the study tells us about heart outcomes
The guide to tirzepatide’s cardiovascular evidence covers trials that measured clinical events. The SURMOUNT analysis counted risk markers. In the separate SURPASS-CVOT trial of adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide for cardiovascular death, heart attack or stroke[2].